Jesal Shah
Directeur/Membre du Conseil chez RIGImmune, Inc.
Profil
Jesal Shah is currently a Director at Aleor Dermaceuticals Ltd.
and RIGImmune, Inc. Previously, Jesal worked as a Research Analyst at JPMorgan India Pvt Ltd.
and as the Head of Research & Research Analyst at JM Financial Institutional Securities Ltd.
Postes actifs de Jesal Shah
| Sociétés | Poste | Début |
|---|---|---|
RIGImmune, Inc.
 RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Directeur/Membre du Conseil | - |
Aleor Dermaceuticals Ltd.
 Aleor Dermaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aleor Dermaceuticals Ltd. is an Indian company that develops and commercializes dermatology products. The joint venture company was founded in 2016. The company is based in Vadodara, India. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jesal Shah
| Sociétés | Poste | Fin |
|---|---|---|
JPMorgan India Pvt Ltd.
 JPMorgan India Pvt Ltd. Investment Banks/BrokersFinance JPMorgan India Pvt Ltd. is the Indian broker-dealer subsidiary of JPMorgan Securities India Pvt Ltd. and their ultimate parent is JPMorgan Chase & Co. (NYSE: JPM) in the US. Headquartered in Mumbai, JPMorgan India provides clients in India with a comprehensive range of corporate and investment banking services. | Analyst-Equity | 01/10/2007 |
JM Financial Institutional Securities Ltd.
 JM Financial Institutional Securities Ltd. Investment Banks/BrokersFinance JM Financial Institutional Securities Ltd. (JMF-IS) is the securities arm of JM Financial Services Ltd., which is owned by JM Financial Ltd. (NSE: JMFINANCIL), an integrated financial services group based in India. Headquartered in Mumbai, the firm was founded in 1995 as ASK-Raymond James & Associates Pvt Ltd., a joint venture between India-based ASK Investment and Financial Consultants Ltd., US-based Raymond James Financial, Inc. and Bharat Shah. JMF-IS provides trade execution services as well as research and analysis with a strong focus on the Indian economy. Their clients are domestic and offshore institutions, high-net worth individuals and non-resident Indians. | Directeur de la Recherche - Actions | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
JPMorgan India Pvt Ltd.
JPMorgan India Pvt Ltd. Investment Banks/BrokersFinance JPMorgan India Pvt Ltd. is the Indian broker-dealer subsidiary of JPMorgan Securities India Pvt Ltd. and their ultimate parent is JPMorgan Chase & Co. (NYSE: JPM) in the US. Headquartered in Mumbai, JPMorgan India provides clients in India with a comprehensive range of corporate and investment banking services. | Finance |
RIGImmune, Inc.
RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Commercial Services |
JM Financial Institutional Securities Ltd.
JM Financial Institutional Securities Ltd. Investment Banks/BrokersFinance JM Financial Institutional Securities Ltd. (JMF-IS) is the securities arm of JM Financial Services Ltd., which is owned by JM Financial Ltd. (NSE: JMFINANCIL), an integrated financial services group based in India. Headquartered in Mumbai, the firm was founded in 1995 as ASK-Raymond James & Associates Pvt Ltd., a joint venture between India-based ASK Investment and Financial Consultants Ltd., US-based Raymond James Financial, Inc. and Bharat Shah. JMF-IS provides trade execution services as well as research and analysis with a strong focus on the Indian economy. Their clients are domestic and offshore institutions, high-net worth individuals and non-resident Indians. | Finance |
Aleor Dermaceuticals Ltd.
Aleor Dermaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aleor Dermaceuticals Ltd. is an Indian company that develops and commercializes dermatology products. The joint venture company was founded in 2016. The company is based in Vadodara, India. | Health Technology |
